Fennec Pharmaceuticals General and Administrative Expenses 2011-2026 | FENC

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Fennec Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
20.6 M	17.7 M	12.2 M	13 M	7.4 M	5.4 M	5.02 M	2.4 M	1.63 M	2.52 M	1.33 M	1.54 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
20.6 M	1.33 M	7.56 M

Quarterly General and Administrative Expenses Fennec Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
6.75 M	6.96 M	6.14 M	-	6.12 M	6.86 M	5.87 M	-	3.8 M	5.5 M	4.32 M	-	7.05 M	3.88 M	2.11 M	-	2.93 M	3.12 M	2.51 M	-	4.49 M	3.72 M	2.44 M	-	1.07 M	2.84 M	1.01 M	-	1.05 M	1.87 M	1.1 M	-	1.69 M	1.15 M	546 K	-	452 K	568 K	407 K	-	250 K	495 K	409 K	-	531 K	858 K	505 K	-	275 K	373 K	359 K	-	273 K	390 K	320 K	-	505 K	338 K	706 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.05 M	250 K	2.33 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
AbCellera Biologics ABCL	83.2 M	$ 3.74	3.6 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	78.7 M	$ 3.36	0.86 %	$ 1.2 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	180 M	$ 29.16	-3.54 %	$ 1.69 B	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Завод ДИОД DIOD	19.7 M	-	-	-	Russia
Фармсинтез LIFE	24.1 M	-	-	-	Russia
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	54 M	$ 2.19	-9.77 %	$ 226 M	USA
Entera Bio Ltd. ENTX	4.89 M	$ 1.38	-0.72 %	$ 63.3 M	Israel
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	13.9 M	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	21 M	$ 4.21	-2.32 %	$ 299 M	USA
Teligent, Inc. TLGT	23.4 M	-	-13.85 %	$ 16.1 M	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	7.25 M	$ 0.84	-4.24 %	$ 27.9 M	Israel
Viela Bio, Inc. VIE	60.2 M	-	-	$ 2.91 B	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	200 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
AbbVie ABBV	14 B	$ 233.57	0.64 %	$ 413 B	USA
Blueprint Medicines Corporation BPMC	359 M	-	-	$ 8.14 B	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
AIM ImmunoTech AIM	13.1 M	$ 0.8	-11.6 %	$ 38.5 M	USA
Aptorum Group Limited APM	5.41 M	$ 0.83	5.37 %	$ 4.53 M	China
Apellis Pharmaceuticals APLS	550 M	$ 20.67	-1.38 %	$ 2.61 B	USA
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Cleveland BioLabs, Inc. CBLI	2.16 M	-	-7.31 %	$ 49 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA